Market News & Trends
Symbiosis Begins Commercial Manufacturing at New FDA-Inspected Facility
Symbiosis Pharmaceutical Services (Symbiosis) has recently manufactured its first 10,000 vial batch at the company’s new facility in Stirling, UK. The project, delivered for one of…
Medicus Pharma Announces Engagement With Reliant AI to Develop AI-Driven Clinical Data Analytics Platform
Medicus Pharma Ltd. recently announced it has entered into non-binding letter of intent (LOI) with Reliant AI Inc., a decision-intelligence company for the life sciences, specializing in…
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of a Novel WRN Inhibitor for MSI-H Tumors
Nimbus Therapeutics, LLC recently announced the completion of dose escalation (Part A) in its Phase 1/2 clinical trial of NDI-219216, the company’s investigational non-covalent Werner…
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy
MediciNova, Inc. recently announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in…
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
Brainomix recently announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective…
PADCEV Plus Keytruda Significantly Improves Survival for Patients With Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Astellas Pharma Inc. and Pfizer Inc. recently announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as…
BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator
BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has joined the Basel-based incubator, bringing the total…
Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data
Affibody AB recently announced the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271…
Lindus Health & Quotient Sciences Partner to Accelerate Drug Development From First-in-Human to Pivotal Trials
Lindus Health and Quotient Sciences have announced a strategic partnership to enable innovative biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and…
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Bicycle Therapeutics plc (NASDAQ: BCYC) recently announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA)…
Peapod Bio & Enamine Announce Strategic Collaboration
Peapod Bio Inc. recently announced a strategic collaboration with Enamine, enabling Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s…
Tjoapack Announces Major US Expansion to Improve Packaging & Logistics Capabilities
Tjoapack recently announced a significant strategic investment to expand its operational footprint in the U.S., strengthening its position as a trusted partner in pharmaceutical supply…
Medicus Pharma Completes Enrollment of 90 Patients for Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. recently announced its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat nodular basal…
FDA Approves First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults & Adolescents
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. recently announced the US FDA has approved NUZOLVENCE (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication…
Nanexa & Moderna Enter License & Option Agreement for the Development of PharmaShell®-Based Products
Nanexa AB recently announced the signing of a license and option agreement with Moderna, Inc. Under the agreement, Moderna receives a license to use Nanexa’s…
Bora Pharmaceuticals & Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
Bora Pharmaceuticals Co., Ltd. and Corealis Pharma Inc. have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and…
Neupulse Launches First-of-its-Kind Wearable With the Support of Ensera Design to Help People Living With Tourette Syndrome
Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people living with Tourette Syndrome,…
Enterprise Therapeutics Publishes Results of Phase 1 Study of a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrsosis1. The paper, titled ETD001, a long-acting inhaled…
Pace Appoints Ken Beyer as Chief Executive Officer
[caption id="attachment_147564" align="alignleft" width="140"] Ken Beyer Pace's new Chief Executive Officer[/caption] Pace, a leading science and technology company with a nationwide network of environmental and…
Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients From Phase 2a Trial of TAZBENTETOL
Spinogenix, Inc. recently announced encouraging results from its completed Phase 2a trial evaluating Tazbentetol (formerly named SPG302) for the treatment of Alzheimer’s disease (AD). Once-daily…
